Why I believe these 3 stocks will struggle in 2017

These three companies are in danger of generating losses for investors next year.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

2017 is just around the corner and City analysts are picking their top stocks for the 12 months ahead. As well as the stocks I’m betting on for 2017, there are some companies I want to avoid next year as headwinds for these firms grow.

Indeed, I believe shares in Reckitt Benckiser (LSE: RB) will come under pressure next year as so-called ‘bond proxy’ stocks continue to fall out of favour with investors. 

Bond proxies are equities that have become an alternative to bonds as interest rates on bonds plunge into negative territory. Defensive companies such as Reckitt are prime proxies as their cash flows are considered safe, helping long-term dividend sustainability. However, as bond yields around the world are now pushing higher, these bond proxies are becoming less popular. 

It’s easy to see why. Yes, these are high-quality businesses, but the reach for yield has pushed their valuations up to record levels. Shares in Reckitt currently trade at a forward P/E of 22.9, down from last year’s 23.9 but still far above peer Unilever’s 19.7. I expect Reckitt’s shares to fall next year as investors rebalance away from bond proxies back towards bonds.

Revenues falling 

AstraZeneca (LSE: AZN) is another company I’m avoiding for 2017. This year, Astra’s most successful drug Crestor came off patent, and the full extent of this patent expiry isn’t yet known. 

According to City consensus, Astra’s top line is expected to fall by 5.8% next year due to management inability to rekindle the company’s pipeline growth. During the third quarter of this year, total product sales were down by 14% at $5bn, as Crestor and Nexium sales declined by 82% and 50% respectively in the US. For the quarter, the company reported a $1bn loss but earnings per share rose 4% to $0.80 thanks to a $453m tax benefit. 

As Astra’s earnings continue to contract with falling sales, it may be wise to avoid the drug maker next year.

Profits evaporate 

Finally, Rolls-Royce (LSE: RR) is a struggling engineer I’m avoiding next year. It has plenty of problems. From falling marine sales as a result of the oil price collapse, to faulty engines delivered to one of its largest customers Emirates, Rolls-Royce is struggling to get things right. What’s more, a new accounting change, whereby the company can’t immediately recognise revenue generated over the life of its engine service contracts immediately, will decimate profitability next year. Under the new accounting rules, Rolls’ 2015 profits would have been £900m lower than the £1.4bn reported. It’s not entirely clear how this change will impact profitability next year, but it’s evident the company will take a big hit to earnings. 

With profits set to tank and problems for the group brewing, Rolls might be one to avoid next year.

Rupert Hargreaves owns shares of Rolls-Royce. The Motley Fool UK owns shares of and has recommended Unilever. The Motley Fool UK has recommended AstraZeneca and Reckitt Benckiser. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

A handsome mature bald bearded black man in a sunglasses and a fashionable blue or teal costume with a tie is standing in front of a wall made of striped wooden timbers and fastening a suit button
Investing Articles

Is NIO stock the next Tesla?

The NIO share price is up by more than 100% in the past year. Might this Chinese EV firm be…

Read more »

Two business people sitting at cafe working on new project using laptop. Young businesswoman taking notes and businessman working on laptop computer.
Investing Articles

Is this the beginning of a stock market recovery?

Dr James Fox explores whether a stock market recovery is truly on the cards after the US struck a deal…

Read more »

Smiling white woman holding iPhone with Airpods in ear
Investing Articles

Up just 1%: what’s going on with Tesco shares now?

Dr James Fox takes a closer look at Tesco shares after the stock rose less than the rest of the…

Read more »

Rear view image depicting a senior man in his 70s sitting on a bench leading down to the iconic Seven Sisters cliffs on the coastline of East Sussex, UK. The man is wearing casual clothing - blue denim jeans, a red checked shirt, navy blue gilet. The man is having a rest from hiking and his hiking pole is leaning up against the bench.
Investing Articles

How much do I need in a Stocks and Shares ISA to reach a £2,027 monthly passive income?

The new financial year is under way and that means new allowances for the Stocks and Shares ISA! How much…

Read more »

UK coloured flags waving above large crowd on a stadium sport match.
Investing Articles

Why is everyone suddenly buying this dirt-cheap growth stock?

This beaten-down UK growth stock has suddenly become the centre of attention as investors target its recovery potential. The Iran…

Read more »

Finger clicking a button marked 'Buy' on a keyboard
Investing Articles

Why is everyone buying Rolls-Royce shares?

Rolls-Royce shares jumped 10% today, even giving mining stocks a run for their money as the FTSE 100 index suddenly…

Read more »

Shot of a senior man drinking coffee and looking thoughtfully out of a window
Investing Articles

Up 8%: what’s going on with Lloyds shares today?

Dr James Fox takes a closer look at one of the stock market's biggest gainers on Wednesday 8 April after…

Read more »

piggy bank, searching with binoculars
Investing Articles

Fresnillo share price rebounds as a FTSE 100 top mover after a 30% sell-off — what’s next?

The Fresnillo share price has surged today — Andrew Mackie asks whether this FTSE 100 mover is signalling a turning…

Read more »